Reviewer's report

Title: HER-2, p53, p21 and hormonal receptors proteins expression as predictive factors of response and prognosis in locally advanced breast cancer treated with neoadjuvant docetaxel plus epirubicin combination

Version: 1 Date: 29 October 2006
Reviewer: Susanne Taucher

Reviewer's report:

General

-----------------------------------------------------------------------------------
Major Compulsory Revisions (that the author must respond to before a decision on publication can be reached)

-----------------------------------------------------------------------------------
Minor Essential Revisions (such as missing labels on figures, or the wrong use of a term, which the author can be trusted to correct)

1. which procedure was performed to diagnose breast cancer.
2. what was the rationale to give 9 cycles of chemotherapy
3. tumordiameter at the time of diagnoses should be described
4. did you evaluate menopausal status before and after chemotherapy?
5. the authors stated that 60 patients were consecutively included in this trial. which inclusion criteria were used?

-----------------------------------------------------------------------------------
Discretionary Revisions (which the author can choose to ignore)

What next?: Accept after minor essential revisions

Level of interest: An article of importance in its field

Quality of written English: Needs some language corrections before being published

Statistical review: No

Declaration of competing interests:

I declare that I have no competing interests